Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases
用抗原 RNA 激活基因表达来治疗遗传性疾病
基本信息
- 批准号:8037089
- 负责人:
- 金额:$ 5.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-12-01 至 2012-11-30
- 项目状态:已结题
- 来源:
- 关键词:CellsChemistryChildhoodChromatinChromatin StructureCodeComplementary DNADNADatabasesDevelopmentDiseaseFMR1FMR1 GeneFragile X SyndromeFunctional Magnetic Resonance ImagingFunctional RNAGene ActivationGene ExpressionGene Expression ProfileGenesGenetic TranscriptionGenomicsHereditary DiseaseHigher Order Chromatin StructureHistone AcetylationHistonesLaboratoriesLongevityMediatingMessenger RNAMethodsMethylationMolecular TargetMuscular DystrophiesPatientsPharmaceutical PreparationsPromoter RegionsProteinsQuality of lifeRNARNA Polymerase IIRecruitment ActivityResearchReverse TranscriptionSMN2 geneSmall Interfering RNASpinal Muscular AtrophyStructureTherapeuticTherapeutic AgentsTimeTranscriptUtrophinantigenechromatin remodelingdesignnovel therapeuticspromoterresearch study
项目摘要
DESCRIPTION (provided by applicant): The common genetic diseases muscular dystrophy (MD), spinal muscular atrophy (SMA) and fragile X syndrome (FXS) have crippling effects on childhood development. They share in common the fact that they can potentially be treated by increasing expression of a single disease-related gene. However, pharmacological activation of gene expression is not typically considered an option for therapeutic treatments due to the non-specific effects of most drugs. Recently the Corey laboratory discovered a robust and specific method for increasing expression of select genes. Small duplex RNAs, called antigene RNAs (agRNAs), are targeted to gene promoters to turn on transcription. These agRNAs actually interact with ubiquitous non-coding RNAs that span gene promoters to elicit changes in local chromatin structure, thus resulting in increased gene expression. The disease-related genes for MD, SMA and FXS all have non- coding RNAs associated with their gene promoter regions and their promoters are well-defined, important features for the successful use of agRNAs. The proposed research will fully characterize non-coding RNA transcripts that span the promoter of each disease-related gene. agRNAs will then be designed to target disease-related gene promoters and screened to identify those that can activate gene expression. Finally, key features of agRNA-mediated gene activation will be investigated to understand agRNA mechanism and help establish efficient agRNA design rules. The results of this study will lay the groundwork for developing agRNAs as novel therapeutic agents to ultimately treat debilitating genetic diseases like MD, SMA and FXS that require increased expression of specific genes. Muscular dystrophy, spinal muscular atrophy and fragile X syndrome are just a few of the many debilitating disorders that disrupt proper childhood development, resulting in a poor quality of life and dramatically shortened lifespans. Treatments for these diseases often lie in increasing the expression of select genes, which is not an option with currently available drugs. The results from this proposed research will provide evidence for antigene RNAs as potential gene-specific drugs and open the door for the first time to treatments for many diseases that require specific increases in gene expression.
描述(由申请人提供):常见的遗传疾病会导致肌肉营养不良(MD),脊柱肌肉萎缩(SMA)和脆弱的X综合征(FXS)对儿童发育有严重的影响。他们共有一个事实,即可以通过增加与疾病相关的基因的表达来治疗它们。但是,由于大多数药物的非特异性作用,基因表达的药理激活通常不被视为治疗治疗的一种选择。最近,科里实验室发现了一种可增加某些基因表达的强大而特定的方法。小型双链RNA,称为抗氮Nas(AgrNA),针对基因启动子来打开转录。这些AGRNA实际上与无处不在的非编码RNA相互作用,这些非编码RNA跨越基因启动子引起局部染色质结构的变化,从而导致基因表达增加。 MD,SMA和FXS的疾病相关基因均具有与其基因启动子区域及其启动子相关的非编码RNA,其定义明确,重要的特征是成功使用AgrNA。拟议的研究将充分表征跨越每个与疾病相关基因的启动子的非编码RNA转录物。然后,AGRNA将被设计为靶向与疾病相关的基因启动子并进行筛选以鉴定可以激活基因表达的基因。最后,将研究AgRNA介导的基因激活的关键特征,以了解AgRNA机制并有助于建立有效的AgRNA设计规则。这项研究的结果将为开发AgrNA作为新型治疗剂的基础,以最终治疗需要增加特定基因表达的MD,SMA和FXS等遗传疾病。肌肉营养不良,脊柱肌肉萎缩和脆弱的X综合征只是破坏适当童年发育的众多令人衰弱的疾病中的一些,导致生活质量差和寿命缩短。这些疾病的治疗通常在于增加某些基因的表达,这不是当前可用的药物的选择。这项拟议研究的结果将为抗基因RNA作为潜在基因特异性药物提供证据,并首次打开大门,以治疗许多需要特定基因表达的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Keith Thomas Gagnon其他文献
Keith Thomas Gagnon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Keith Thomas Gagnon', 18)}}的其他基金
Toward synthetic chemically defined mRNA for human therapeutics
用于人类治疗的合成化学定义的 mRNA
- 批准号:
10649299 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
- 批准号:
10864412 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
表观转录组学与持续残留 HIV 感染的分子疾病机制和核酸治疗的耦合
- 批准号:
10462348 - 财政年份:2022
- 资助金额:
$ 5.13万 - 项目类别:
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
表观转录组学与持续残留 HIV 感染的分子疾病机制和核酸治疗的耦合
- 批准号:
10615203 - 财政年份:2022
- 资助金额:
$ 5.13万 - 项目类别:
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
表观转录组学与持续残留 HIV 感染的分子疾病机制和核酸治疗的耦合
- 批准号:
10907304 - 财政年份:2022
- 资助金额:
$ 5.13万 - 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
- 批准号:
10079496 - 财政年份:2020
- 资助金额:
$ 5.13万 - 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
- 批准号:
10551318 - 财政年份:2020
- 资助金额:
$ 5.13万 - 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
- 批准号:
10322116 - 财政年份:2020
- 资助金额:
$ 5.13万 - 项目类别:
Discovery of Small Molecules that Block Supt4h1-Supt5h Dimerization for Potential C9FTD/ALS Therapeutics
发现阻止 Supt4h1-Supt5h 二聚化的小分子,用于潜在的 C9FTD/ALS 治疗
- 批准号:
9809219 - 财政年份:2019
- 资助金额:
$ 5.13万 - 项目类别:
Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases
用抗原 RNA 激活基因表达来治疗遗传性疾病
- 批准号:
8197067 - 财政年份:2009
- 资助金额:
$ 5.13万 - 项目类别:
相似国自然基金
水相液滴化学在污染物分析、中间体监测、有机合成和污染物降解中的应用
- 批准号:22376048
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
新骨架紫杉烷二萜baccataxane的化学合成、衍生化和降糖活性研究
- 批准号:82373758
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
化学小分子激活YAP诱导染色质可塑性促进心脏祖细胞重编程的表观遗传机制研究
- 批准号:82304478
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
超低温钠离子电池CEI膜原位构筑、界面输运机制及电化学性能研究
- 批准号:52302260
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
开放环境下终身强化学习方法研究及应用
- 批准号:62376122
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
相似海外基金
Engineering of Polymeric Particles for Fetal Therapy
用于胎儿治疗的聚合物颗粒工程
- 批准号:
10586282 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
ADEPT-STAR therapy for high risk neuroblastoma
ADEPT-STAR 治疗高危神经母细胞瘤
- 批准号:
10760738 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis
二氧化硅纳米胶囊介导的 CRISPR 碱基编辑器 mRNA 和等位基因特异性 sgRNA 非病毒传递用于 Leber 先天性黑蒙的基因校正
- 批准号:
10668166 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Inducing H3F3A exon skipping with antisense oligonucleotides as an approach to treat diffuse intrinsic pontine glioma
用反义寡核苷酸诱导 H3F3A 外显子跳跃作为治疗弥漫性内源性脑桥胶质瘤的方法
- 批准号:
10677284 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapy
将 PRC1.1 定义为谱系可塑性和抗 GD2 治疗反应的看门人
- 批准号:
10644278 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别: